Pancreatic cancer: Early detection, diagnosis, and screening

被引：2
作者：
Suzuki R. [1 ]
Ohira H. [2 ]
Irisawa A. [2 ,3 ]
Bhutani M.S. [1 ]
机构：
[1] Department of Gastroenterology, Hepatology and Nutrition Unit 1466, Anderson Cancer Center, Houston, TX 77030
[2] Department of Gastroenterology and Rheumatology, Fukushima Medical University, School of Medicine, Fukushima
[3] Department of Gastroenterology, Fukushima Medical University, Aizu Medical Center Preparatory Office, Fukushima
来源：
Clinical Journal of Gastroenterology | 2012年 / 5卷 / 5期
关键词：
Diagnosis; Pancreatic cancer; Risk factor; Screening;
D O I：
10.1007/s12328-012-0327-0
中图分类号：
学科分类号：
摘要：
Pancreatic cancer, pancreatic ductal adenocarcinoma, is one of the most lethal malignancies, and researchers have therefore intensified efforts directed at its early detection and management. Early detection includes an effective screening program, as pancreatic cancer is known to evolve from precursor lesions, which can be identified using currently available diagnostic modalities. A recent multicenter trial (the CAPS 3 trial) demonstrated that screening of asymptomatic individuals at high risk for pancreatic cancer frequently detects small cystic pancreatic lesions, including curable, noninvasive high-grade neoplasms. In that study, endoscopic ultrasound and magnetic resonance imaging were better at detecting pancreatic lesions than was computed tomography. On the other hand, effective screening modalities (e.g., imaging studies with measurement of biomarkers) are lacking for individuals at normal to moderate risk for this disease. Therefore, pancreatic cancer screening strategies should include identification of the population at high risk for this cancer and intensive application of screening tools with adequate sensitivity to detect early-stage disease. © Springer 2012.
引用
收藏
页码：322 / 326
页数：4
相关论文
共 55 条
  • [1] Bradley J., Bae K., Choi N., Forster K., Siegel B.A., Brunetti J., Et al., A phase ii comparative study of gross tumor volume definition with or without pet/ct fusion in dosimetric planning for nonsmall-cell lung cancer (nsclc): Primary analysis of radiation therapy oncology group (rtog) 0515, Int J Radiat Oncol Biol Phys, 82, 435-441, (2012)
  • [2] Rulyak S.J., Kimmey M.B., Veenstra D.L., Brentnall T.A., Costeffectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds, Gastrointest Endosc, 57, pp. 23-8, (2003)
  • [3] Brand R.E., Lerch M.M., Rubinstein W.S., Neoptolemos J.P., Whitcomb D.C., Hruban R.H., Et al., Advances in counselling and surveillance of patients at risk for pancreatic cancer, Gut, 56, pp. 1460-8, (2007)
  • [4] Brand R.E., Lynch H.T., Hereditary pancreatic adenocarcinoma. A clinical perspective, Med Clin North Am, 84, pp. 665-75, (2000)
  • [5] Lynch H.T., Fitzsimmons M.L., Smyrk T.C., Lanspa S.J., Watson P., McClellan J., Et al., Familial pancreatic cancer: Clinicopathologic study of 18 nuclear families, Am J Gastroenterol, 85, pp. 54-60, (1990)
  • [6] Schneider R., Slater E.P., Sina M., Habbe N., Fendrich V., Matthai E., Et al., German national case collection for familial pancreatic cancer (fapaca): Ten years experience, Fam Cancer, 10, pp. 323-30, (2011)
  • [7] McFaul C.D., Greenhalf W., Earl J., Howes N., Neoptolemos J.P., Kress R., Et al., Anticipation in familial pancreatic cancer, Gut, 55, pp. 252-8, (2006)
  • [8] Tersmette A.C., Petersen G.M., Offerhaus G.J., Falatko F.C., Brune K.A., Goggins M., Et al., Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer, Clin Cancer Res, 7, pp. 738-44, (2001)
  • [9] Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M., Bansal R., Et al., Evaluation of candidate genes map2k4, madh4, acvr1b, and brca2 in familial pancreatic cancer: Deleterious brca2 mutations in 17%, Cancer Res, 62, pp. 3789-83, (2002)
  • [10] Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B., Et al., Brca2 germline mutations in familial pancreatic carcinoma, J Natl Cancer Inst, 95, pp. 214-21, (2003)
123456